Zachery R Reichert
Overview
Explore the profile of Zachery R Reichert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mayer C, Walch O, Dempsey W, Hannay K, Clingan C, Bowen Z, et al.
Cell Rep Med
. 2025 Mar;
:102001.
PMID: 40056908
Lighting interventions can mitigate fatigue by promoting circadian rhythmicity. We test whether individualized, wearable-based lighting interventions delivered via a mobile app reduce cancer-related fatigue in a randomized controlled trial with...
2.
Abusamra S, Solorzano M, Quarles J, Luke M, Patel M, Vince Jr R, et al.
Urol Pract
. 2024 Oct;
12(1):63-72.
PMID: 39383006
Introduction: There is increasing awareness that patients with prostate cancer frequently harbor germline variants that may carry important implications for them and their family members. Given the variable clinical guidelines,...
3.
Niu Z, Kozminsky M, Day K, Broses L, Henderson M, Patsalis C, et al.
Neoplasia
. 2024 Aug;
57:101036.
PMID: 39173508
Assessing the molecular profiles of bladder cancer (BC) from patients with locally advanced or metastatic disease provides valuable insights, such as identification of invasive markers, to guide personalized treatment. Currently,...
4.
Caram M, Kumbier K, Tsao P, Burns J, Sparks J, Stensland K, et al.
Cancer Med
. 2024 Aug;
13(12):e7334.
PMID: 39143030
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration-resistant diagnosis. Optimal first-line therapy for those with different prognoses...
5.
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller C, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4318-4328.
PMID: 39115414
Purpose: Deleterious germline/somatic homologous recombination repair mutations (HRRm) are present in ∼25% of patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinically, poly(ADP-ribose) polymerase (PARP) inhibition demonstrated synergism with androgen receptor...
6.
Nguyen C, Reimers M, Perera C, Abida W, Chou J, Feng F, et al.
Clin Cancer Res
. 2024 May;
30(15):3200-3210.
PMID: 38787530
Purpose: CDK12 inactivation in metastatic castration-resistant prostate cancer (mCRPC) may predict immunotherapy responses. This phase 2 trial evaluated the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with CDK12-altered...
7.
Abdulfatah E, Brown N, Davenport M, Reichert Z, Camelo-Piragua S, Heider A, et al.
Hum Pathol
. 2024 May;
148:41-50.
PMID: 38697270
Extragonadal germ cell tumors (EGCTs) are rare, representing <5% of all germ cell tumors (GCTs). Whilst EGCTs share morphological and immunohistochemical features with their gonadal counterparts, they tend to be...
8.
Andino J, Sessine M, Singhal U, Reichert Z, Wray D, Shafer C, et al.
Urol Pract
. 2023 Apr;
8(2):225.
PMID: 37064605
No abstract available.
9.
A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer
Tsung I, Green E, Palmbos P, Sloan Z, Reichert Z, Vaishampayan U, et al.
J Urol
. 2022 Nov;
209(1):121-130.
PMID: 36317715
Purpose: Immune checkpoint inhibitor therapy and nab-paclitaxel have each shown efficacy in platinum-refractory advanced urothelial cancer. We conducted a single-arm phase 2 trial of the combination of nab-paclitaxel and pembrolizumab...
10.
Cantley R, Wang X, Reichert Z, Chinnaiyan A, Mannan R, Cao X, et al.
Cancer Cytopathol
. 2022 Oct;
131(2):117-135.
PMID: 36264673
Introduction: The diagnosis of metastatic prostatic cancer (MPC) by fine needle aspiration (FNA) can usually be rendered by typical cytomorphologic and immunohistochemical (IHC) features. However, MPC diagnosis may be complicated...